LuciAcal (Acalabrutinib) 100mg*60 | Lucius Laos Generic | GLT

Generic Information: LuciAcal (Acalabrutinib) 100mg — Laos

LuciAcal is a Lao-manufactured generic of acalabrutinib from Lucius Pharmaceuticals (Lao) Co., Ltd., a Vientiane-based manufacturer with an extensive oncology portfolio. The product is supplied as 100 mg capsules in 60-capsule packs. LuciAcal is Lucius's acalabrutinib brand for mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.

Lucius Pharmaceuticals uses a distinctive "Luci" prefix across its oncology line, so buyers familiar with other Lucius products will recognise LuciAcal as its acalabrutinib offering. Acalabrutinib is a highly selective, second-generation BTK inhibitor originally developed as Calquence, and the 100 mg capsule is the standard strength used in the twice-daily regimen.

What Is LuciAcal Used For?

LuciAcal treats mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It delivers continuous, covalent BTK inhibition to control these B-cell blood cancers.

How Does LuciAcal Work?

Acalabrutinib, the active ingredient in LuciAcal, covalently binds to Bruton's tyrosine kinase (BTK), irreversibly blocking the enzyme. BTK relays survival and proliferation signals from the B-cell antigen receptor, so its inhibition disrupts the growth of the malignant B cells underlying MCL, CLL and SLL.

Indications

• Mantle cell lymphoma (MCL) after at least one prior therapy.
• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Dosage and Administration

The recommended dose is 100 mg twice daily, taken approximately every 12 hours. Capsules are swallowed whole with water, with or without food, and must not be chewed or opened. Treatment continues until disease progression or unacceptable toxicity, with regular blood-count and liver-function monitoring.

Side Effects

Common adverse reactions include upper respiratory tract infection, diarrhoea, headache, fatigue, nausea and musculoskeletal pain. More serious risks include bleeding, serious infections, cytopenias, second primary malignancies, atrial fibrillation and liver injury. Patients should report unusual bleeding, palpitations or infection signs promptly.

Storage

Store LuciAcal below 30°C in the original pack, protected from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT verifies each LuciAcal batch against Lucius's documentation and provides a transparent, traceable supply route for Lao generics. Lao-made acalabrutinib is typically priced at a small fraction of the originator's US list price, which makes continuous twice-daily BTK-inhibitor therapy far more sustainable for patients and institutions. We provide clear purchase documentation and direct contact for ongoing support.

How to Order LuciAcal from GLT

To order LuciAcal 100 mg (60 capsules), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and order type, and we confirm batch details and lead time before dispatch.

FAQ

Is LuciAcal the same as Calquence? LuciAcal contains the same active ingredient (acalabrutinib) at 100 mg; it is a generic manufactured in Laos by Lucius Pharmaceuticals.

What is the standard dose? 100 mg twice daily, approximately every 12 hours, with or without food.

How long does one pack last? A 60-capsule pack lasts 30 days at the standard twice-daily dose.